Group 1 - The company has received feedback from its internal rectification team confirming that the current trial progress is below expectations, and its subsidiary Tianjin Weiming is expected to be unable to resume normal production and operations within three months [1][2] - As a result of the above situation, the company's stock will be subject to "other risk warnings," changing its name from "Weiming Pharmaceutical" to "ST Weiming," with the stock code remaining "002581" and the daily price fluctuation limit changing from 10% to 5% [1][2] - The suspension of production and sales by Tianjin Weiming, which is a significant subsidiary responsible for the production and sales of interferon drugs, has a substantial impact on the company's operations, accounting for 60.09% of the company's revenue and 9.8% of the consolidated net profit [1][2] Group 2 - The company's board of directors acknowledges the adverse effects of the situation and plans to take effective measures to mitigate the impact, including promoting product sales in other markets and increasing efforts in market development and new product development [2] - Other subsidiaries of the company are operating normally and maintaining production capabilities, while the company aims to optimize management, reduce expenses, control costs, and enhance business profitability to ensure stable operations [3] - During the period of other risk warnings, the company will accept investor inquiries through phone and email, ensuring timely responses while adhering to insider information confidentiality regulations [3]

据了解，天津未名主要从事人干扰素药品的生产与销售，2024年实现营收2.17亿元，占公司同期营收的60.09%，与未名生物医 药有限公司同为未名医药两大重要子公司。本次暂停生产、销售事项对公司生产经营产生重要影响，若天津未名三个月内无法 恢复生产，天津未名可能触发其他风险警示(ST)的情形。 海岱财经梳理获知，3月12日以来，未名医药生产的人干扰素α2b喷雾剂因被检验为"生物学活性不符规定"，已被上海、浙江、 内蒙古、西藏等地暂停采购。 4月24日晚间，未名医药（002581）发布公告称，其控股子公司天津未名生物医药有限公司(下称"天津未名")于4月22日被天津市 药品监督管理局采取暂停生产、销售的风险控制措施。 此外，该产品也曾在江西省医保局牵头开展的29省份干扰素省际联盟集中带量采购中中标，但是因抽检结果不合格暂停采购。 据江西省联采办通报，目前涉事批次已启动全面封存召回程序，恢复采购时间将"另行通知"。 未名医药自主研发的人干扰素α2b喷雾剂(捷抚)曾是其核心产品。根据2024年年报，未名医药主要销售产品为鼠神经生长因子和 干扰素产品，这两大类产品合计贡献超90%营收，两类产品毛利率均接近80%。 根据 ...